Promising Nanotechnology Stocks To Add to Your Watchlist - August 10th

Key Points

• Nanotechnology stocks to watch: Seven companies, including Onto Innovation, OSI Systems, and Nano Dimension, are highlighted for their promise in nanotechnology and recent high trading volumes.
• Onto Innovation's market performance: The company’s stock reached $103.07 with a trading volume of over 3.8 million shares, indicating strong interest and a market cap of $5.03 billion.
• Clene’s focus on novel therapeutics: Clene Inc. is advancing clean-surfaced nanotechnology therapeutics, with its candidate CNM-Au8 undergoing multiple clinical trials for conditions like ALS and Parkinson's disease.

Onto Innovation, OSI Systems, NVE, Nano Dimension, Clene, Biodexa Pharmaceuticals, and Clene are the seven Nanotechnology stocks to watch today, according to MarketBeat's stock screener tool. Nanotechnology stocks are shares of publicly traded companies whose core business involves the research, development or commercialization of materials, devices and systems engineered at the nanoscale (one billionth of a meter). These companies may work on applications ranging from advanced medical diagnostics and drug delivery to improved electronic components and industrial catalysts. Investors buy these stocks to gain exposure to the potential growth and innovation driven by nanoscale science and engineering. These companies had the highest dollar trading volume of any Nanotechnology stocks within the last several days.

Onto Innovation (ONTO)

Onto Innovation Inc. engages in the design, development, manufacture, and support of process control tools that performs optical metrology. The company offers lithography systems and process control analytical software. It also offers process and yield management solutions, and device packaging and test facilities through standalone systems for optical metrology, macro-defect inspection, packaging lithography, and transparent and opaque thin film measurements.

Onto Innovation stock traded up $10.39 during midday trading on Friday, reaching $103.07. The company's stock had a trading volume of 3,811,045 shares, compared to its average volume of 1,208,913. The stock has a market cap of $5.03 billion, a PE ratio of 25.51, a price-to-earnings-growth ratio of 0.67 and a beta of 1.44. Onto Innovation has a 52 week low of $85.88 and a 52 week high of $228.42. The business has a 50-day moving average price of $98.30 and a 200-day moving average price of $123.05.

Read Our Latest Research Report on ONTO

OSI Systems (OSIS)

OSI Systems, Inc. designs and manufactures electronic systems and components. It operates in three segments: Security, Healthcare, and Optoelectronics and Manufacturing. The Security segment offers baggage and parcel inspection, cargo and vehicle inspection, hold baggage and people screening, radiation monitoring, explosive and narcotics trace detection systems, and optical inspection systems under the Rapiscan name.

OSI Systems stock traded up $2.01 during trading hours on Friday, hitting $225.94. The stock had a trading volume of 141,174 shares, compared to its average volume of 147,971. The company has a quick ratio of 1.38, a current ratio of 2.11 and a debt-to-equity ratio of 0.53. The stock has a market cap of $3.79 billion, a price-to-earnings ratio of 27.49, a P/E/G ratio of 1.91 and a beta of 1.31. OSI Systems has a one year low of $129.84 and a one year high of $241.64. The business's 50 day simple moving average is $222.55 and its 200-day simple moving average is $209.57.

Read Our Latest Research Report on OSIS

NVE (NVEC)

NVE Corporation develops and sells devices that use spintronics, a nanotechnology that relies on electron spin to acquire, store, and transmit information in the United States and internationally. The company manufactures spintronic products, including sensors and couplers for use in acquiring and transmitting data.

NVE stock traded down $0.06 during trading hours on Friday, hitting $61.66. The stock had a trading volume of 53,840 shares, compared to its average volume of 62,335. The business's 50 day simple moving average is $71.42 and its 200-day simple moving average is $68.05. NVE has a one year low of $51.50 and a one year high of $88.50. The stock has a market cap of $298.43 million, a price-to-earnings ratio of 20.55 and a beta of 1.19.

Read Our Latest Research Report on NVEC

Nano Dimension (NNDM)

Nano Dimension Ltd., together with its subsidiaries, engages in additive manufacturing solutions in Israel and internationally. The company offers 3D printers, comprising AME systems, which are inkjet printers, that produces Hi-PEDs by depositing proprietary conductive and dielectric substances, as well as integrates in-situ capacitors, antennas, coils, transformers, and electromechanical components; micro additive manufacturing systems, a digital light processing printers (DLP) that achieves production-grade polymer and composite parts; and industrial additive manufacturing systems, that utilizes a patented foil system that fabricates ceramic and metal parts.

Shares of NASDAQ NNDM traded down $0.02 during trading on Friday, reaching $1.33. The company had a trading volume of 1,641,358 shares, compared to its average volume of 2,861,636. The company's fifty day moving average price is $1.49 and its 200-day moving average price is $1.76. Nano Dimension has a 12 month low of $1.32 and a 12 month high of $2.74. The stock has a market cap of $288.99 million, a P/E ratio of -3.32 and a beta of 1.13.

Read Our Latest Research Report on NNDM

Clene (CLNN)

Clene Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel clean-surfaced nanotechnology (CSN) therapeutics. Its lead drug candidate is CNM-Au8, which is being studied in various clinical trials, including a completed Phase 2 platform trial to evaluate the safety and efficacy of CNM-Au8 in patients with amyotrophic lateral sclerosis (ALS); completed Phase 2 proof of concept clinical trial in patients with early symptomatic ALS; completed two open-label investigator blinded Phase 2 clinical trials on the brain's energy metabolites; completed Phase 2 clinical trial for the treatment of visual pathway deficits in chronic optic neuropathy for remyelination in stable relapsing Multiple Sclerosis; and a second Phase 2 clinical trial for the treatment of patients with Parkinson's Diseases.

Shares of CLNN stock traded up $0.01 during mid-day trading on Friday, hitting $3.68. The company's stock had a trading volume of 49,673 shares, compared to its average volume of 73,675. The company's fifty day simple moving average is $3.92 and its 200-day simple moving average is $3.72. Clene has a 52 week low of $2.28 and a 52 week high of $6.90. The company has a market cap of $30.43 million, a PE ratio of -0.91 and a beta of 0.55.

Read Our Latest Research Report on CLNN

Biodexa Pharmaceuticals (BDRX)

Biodexa Pharmaceuticals Plc, a clinical stage biopharmaceutical company, focuses on developing a pipeline of products for the treatment of Type 1 diabetes and rare/orphan cancers of the brain. Its lead product candidate Tolimidone, a selective activator of the lyn kinase enzyme, currently under Phase II studies for the treatment of Type 1 diabetes.

Shares of BDRX stock traded up $0.33 during mid-day trading on Friday, hitting $7.13. The company's stock had a trading volume of 23,694 shares, compared to its average volume of 148,135. The company's fifty day simple moving average is $9.14 and its 200-day simple moving average is $18.60. The company has a debt-to-equity ratio of 0.01, a quick ratio of 1.75 and a current ratio of 1.75. Biodexa Pharmaceuticals has a 52 week low of $5.85 and a 52 week high of $163.10.

Read Our Latest Research Report on BDRX

Clene (CLNNW)

Clene Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel clean-surfaced nanotechnology (CSN) therapeutics. Its lead drug candidate is CNM-Au8, which is being studied in various clinical trials, including a completed Phase 2 platform trial to evaluate the safety and efficacy of CNM-Au8 in patients with amyotrophic lateral sclerosis (ALS); completed Phase 2 proof of concept clinical trial in patients with early symptomatic ALS; completed two open-label investigator blinded Phase 2 clinical trials on the brain's energy metabolites; completed Phase 2 clinical trial for the treatment of visual pathway deficits in chronic optic neuropathy for remyelination in stable relapsing Multiple Sclerosis; and a second Phase 2 clinical trial for the treatment of patients with Parkinson's Diseases.

Shares of CLNNW stock traded down $0.00 on Friday, reaching $0.03. 60,921 shares of the company were exchanged, compared to its average volume of 11,061. The company has a 50-day moving average of $0.03 and a 200-day moving average of $0.03. Clene has a one year low of $0.02 and a one year high of $0.08.

Read Our Latest Research Report on CLNNW

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.